Prince Andrew's former ties to a suspected Chinese spy caused him to stay away from Thursday's traditional royal family ...

Merck has entered into a global licensing agreement with Chinese biopharmaceutical company Hansoh Pharma to develop an oral small molecule GLP-1 receptor agonist, HS-10535.

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.

Shares of Merck & Co (MRK) continue to trend lower. If they reach the $95.00 level, there is a good chance they find support ...

Viking Therapeutics has seen a significant drop, despite positive news and promising GLP-1 drug developments. Find out why ...

Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh ...

MSD is also betting on Hansoh’s candidate working in more indications than just obesity. The drugmaker already has a ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

The big pharma is paying Hansoh $112 million upfront to place its bet on oral GLP-1 receptor agonist HS-1035, with another $1 ...

The server maker has been on a roller coaster, getting caught up in the excitement about artificial intelligence which helped shares lift to a March high, but worries about accounting dragged them ...